QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ekins, S. Articles by Harrison, R. K. Search for Related Content PubMed PubMed Citation Articles by Ekins, S. Articles by Harrison, R. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

SHORT COMMUNICATION

GENERATION AND VALIDATION OF RAPID COMPUTATIONAL FILTERS FOR CYP2D6 AND CYP3A4

Concurrent Pharmaceuticals Inc., Fort Washington, Pennsylvania

CYP2D6 and CYP3A4 represent two particularly important members of the cytochrome P450 enzyme family due to their involvement in the metabolism of many commercially available drugs. Avoiding potent inhibitory interactions with both of these enzymes is highly desirable in early drug discovery, long before entering clinical trials. Computational prediction of this liability as early as possible is desired. Using a commercially available data set of over 1750 molecules to train computer models that were generated with commercially available software enabled predictions of inhibition for CYP2D6 and CYP3A4, which were compared with empirical data. The results suggest that using a recursive partitioning (tree) technique with augmented atom descriptors enables a statistically significant rank ordering of test-set molecules (Spearman's of 0.61 and 0.48 for CYP2D6 and CYP3A4, respectively), which represents an increased rate of identifying the best compounds when compared with the random rate. This approach represents a valuable computational filter in early drug discovery to identify compounds that may have P450 inhibition liabilities prior to molecule synthesis. Such computational filters offer a new approach in which lead optimization in silico can occur with virtual molecules simultaneously tested against multiple enzymes implicated in drug-drug interactions, with a resultant cost savings from a decreased level of molecule synthesis and in vitro screening.

This article has been cited by other articles:

				M. Kotsuma, H. Hanzawa, Y. Iwata, K. Takahashi, and T. Tokui Novel Binding Mode of the Acidic CYP2D6 Substrates Pactimibe and Its Metabolite R-125528 Drug Metab. Dispos., September 1, 2008; 36(9): 1938 - 1943. [Abstract] [Full Text] [PDF]

				M. Kotsuma, T. Tokui, T. Ishizuka-Ozeki, T. Honda, H. Iwabuchi, T. Murai, T. Ikeda, and H. Saji CYP2D6-Mediated Metabolism of a Novel Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor, Pactimibe, and Its Unique Plasma Metabolite, R-125528 Drug Metab. Dispos., March 1, 2008; 36(3): 529 - 534. [Abstract] [Full Text] [PDF]

				D. R. Jones, S. Ekins, L. Li, and S. D. Hall Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5) Drug Metab. Dispos., September 1, 2007; 35(9): 1466 - 1475. [Abstract] [Full Text] [PDF]

				S. Ekins, D. C. Mankowski, D. J. Hoover, M. P. Lawton, J. L. Treadway, and H. J. Harwood Jr. Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors Drug Metab. Dispos., March 1, 2007; 35(3): 493 - 500. [Abstract] [Full Text] [PDF]

				D. J. Dix, K. A. Houck, M. T. Martin, A. M. Richard, R. W. Setzer, and R. J. Kavlock The ToxCast Program for Prioritizing Toxicity Testing of Environmental Chemicals Toxicol. Sci., January 1, 2007; 95(1): 5 - 12. [Abstract] [Full Text] [PDF]

				J. Yu, M. J. I. Paine, J.-D. Marechal, C. A. Kemp, C. J. Ward, S. Brown, M. J. Sutcliffe, G. C. K. Roberts, E. M. Rankin, and C. R. Wolf IN SILICO PREDICTION OF DRUG BINDING TO CYP2D6: IDENTIFICATION OF A NEW METABOLITE OF METOCLOPRAMIDE Drug Metab. Dispos., August 1, 2006; 34(8): 1386 - 1392. [Abstract] [Full Text] [PDF]

				S. Ekins, S. Andreyev, A. Ryabov, E. Kirillov, E. A. Rakhmatulin, S. Sorokina, A. Bugrim, and T. Nikolskaya A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT Drug Metab. Dispos., March 1, 2006; 34(3): 495 - 503. [Abstract] [Full Text] [PDF]

				R. Arimoto, M.-A. Prasad, and E. M. Gifford Development of CYP3A4 Inhibition Models: Comparisons of Machine-Learning Techniques and Molecular Descriptors J Biomol Screen, April 1, 2005; 10(3): 197 - 205. [Abstract] [PDF]

				K. V. Balakin, S. Ekins, A. Bugrim, Y. A. Ivanenkov, D. Korolev, Y. V. Nikolsky, A. V. Skorenko, A. A. Ivashchenko, N. P. Savchuk, and T. Nikolskaya KOHONEN MAPS FOR PREDICTION OF BINDING TO HUMAN CYTOCHROME P450 3A4 Drug Metab. Dispos., October 1, 2004; 32(10): 1183 - 1189. [Abstract] [Full Text] [PDF]